Why Jim Cramer Would Sell Allergan (AGN) Stock on Valeant (VRX) Deal
BY Andrew Meola | 05/28/14 - 12:33 PM EDT
NEW YORK (TheStreet) -- TheStreet's Jim Cramer says Herb Greenberg knows Valeant Pharmaceuticals (VRX_) better than anyone, and he has convinced Cramer that the Canadian company's problem is it must make deal after deal to keep its roll up going.
Cramer says it is interesting to see Allergan (AGN_) drop substantially for the first time, which tells him that the deal with Valeant may not be cut and dried yet. Valeant's sale of the rights some of the key drugs it acquired in its takeover of Medicis Pharmaceuticals to Nestle all hinge on this deal with Allergan. He reminds investors that Valeant only bought Medicis a few years ago.
BY Andrew Meola | 05/28/14 - 12:33 PM EDT
NEW YORK (TheStreet) -- TheStreet's Jim Cramer says Herb Greenberg knows Valeant Pharmaceuticals (VRX_) better than anyone, and he has convinced Cramer that the Canadian company's problem is it must make deal after deal to keep its roll up going.
Cramer says it is interesting to see Allergan (AGN_) drop substantially for the first time, which tells him that the deal with Valeant may not be cut and dried yet. Valeant's sale of the rights some of the key drugs it acquired in its takeover of Medicis Pharmaceuticals to Nestle all hinge on this deal with Allergan. He reminds investors that Valeant only bought Medicis a few years ago.